Robust Drug Pipeline Highlights Specialty Pharmacy Week in Review

Top stories of the week on Specialty Pharmacy Times from April 20 to April 24.

Top stories of the week on Specialty Pharmacy Times from April 20 to April 24.

Specialty Drugs Dominate Late-Stage Pipeline

Record number of orphan drugs approved in 2014.

http://www.specialtypharmacytimes.com/news/Specialty-Drugs-Dominate-Late-Stage-Pipeline

Adherence is Paramount in Era of Rising Specialty Drug Costs

Catamaran chief medical officer discusses various trends that will impact specialty medications into the future.

http://www.specialtypharmacytimes.com/news/Adherence-is-Paramount-in-Era-of-Rising-Specialty-Drug-Costs

MS Drug Combination Repairs Damaged Brain Cells, Reverses Paralysis

Topical medications that treat skin conditions prompt stem cells in the brain to repair damage.

http://www.specialtypharmacytimes.com/news/MS-Drug-Combination-Repairs-Damaged-Brain-Cells-Reverses-Paralysis

Pfizer’s Lung Cancer Drug Receives Breakthrough Designation

Pfizer seeking to expand approved use of Xalkori to patients with ROS1-positive non-small cell lung cancer.

http://www.specialtypharmacytimes.com/news/Pfizers-Lung-Cancer-Drug-Receives-Breakthrough-Designation

Protein Inhibition Therapy Holds Promise for Treating Several Cancer Types

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

http://www.specialtypharmacytimes.com/news/Protein-Inhibition-Therapy-Holds-Promise-for-Treating-Several-Cancer-Types

Extending Dose of Multiple Sclerosis Drug Safe and Effective

Pushing treatment with natalizumab from 4 weeks up to 8 weeks shows promising results.

http://www.specialtypharmacytimes.com/news/Extending-Dose-of-Multiple-Sclerosis-Drug-Safe-and-Effective

Multiple Sclerosis Drug Effective Fighting HIV Viral Reservoir

Medication also used in treatment of Crohn’s disease effective at blocking pathways.

http://www.specialtypharmacytimes.com/news/Multiple-Sclerosis-Drug-Effective-Fighting-HIV-Viral-Reservoir

Prostate Cancer Drug Label Updated with Survival Data

Study showed a median overall survival of nearly 3 years with Zytiga plus prednisone.

http://www.specialtypharmacytimes.com/news/Prostate-Cancer-Drug-Label-Updated-with-Survival-Data

Racial Disparities in Cancer Death Rate Declining

Mortality gap in cancer deaths among African Americans and Caucasians may eventually disappear.

http://www.specialtypharmacytimes.com/news/Racial-Disparities-in-Cancer-Death-Rate-Declining

Otezla Shows Promise in Treatment of Rare Inflammatory Disease

Treatment found to improve several measures of disease activity and quality of life in patients with Behçet's disease.

http://www.specialtypharmacytimes.com/news/Otezla-Shows-Promise-in-Treatment-of-Rare-Inflammatory-Disease